The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will take place from May 30 to June 3 at the McCormick Place Convention Center in Chicago, USA. This annual event brings together leading experts in clinical oncology from around the world to showcase the latest advancements in oncology clinical research and cancer treatment technologies. On April 24, 2025 (Central Standard Time), ASCO released the titles of research abstracts accepted for the annual meeting. Four latest clinical studies related to Beijing Biostar’s core products, Utidelone Injection and Utidelone Capsule, will be presented at ASCO 2025 through oral presentations and poster sessions.

Utidelone Injection was approved in China in March 2021 for the treatment of recurrent or metastatic advanced breast cancer, making it the only novel antitumor drug with a new molecular structure among microtubule inhibitors approved globally in the past decade. Based on its advantages, such as blood-brain barrier penetration, broad-spectrum anticancer activity, low hematological toxicity, and potential for oral administration, Beijing Biostar has been actively expanding Utidelone’s indications and developing oral formulations both domestically and internationally. The four selected studies include:

· A Phase I/II clinical trial of Utidelone Capsule for advanced breast cancer (China registration study)

· A Phase I clinical trial of Utidelone Capsule for advanced solid tumors (US registration study)

· A Phase II clinical trial of Utidelone Injection as first-line treatment for advanced gastric and esophageal cancer (China registration study)

· A Phase II clinical trial of Utidelone Injection for breast cancer brain metastasis (China study)

Oral Presentation

Abstract title: Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer patients with brain metastasis: a prospective, single-arm, phase II trial.

Abstract ID: 2012

Session: Central Nervous System Tumors

Presentation time: May 31, 2025 (3 PM, Central Standard Time)

Presenter: Yehui Shi (Tianjin Medical University Cancer Hospital)

Poster Presentation

Abstract title: Efficacy and safety results of a multi-center Phase I study of utidelone capsule, a novel oral microtubule inhibitor, in advanced solid tumors patients.

Abstract ID：3030

Session: Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology

Presentation time: Jun 2, 2025 (1:30-4:30 PM, Central Standard Time)

Presenter: Judy S. Wang（Florida Cancer Specialists/Sarah Cannon Research Institute）

Poster Presentation

Abstract title: Efficacy and safety results of a multi-center Phase II study of utidelone injection in combination with PD-1 inhibitor and chemotherapy for the first-line treatment of advanced gastric and esophageal cancers.

Abstract ID：4040

Session: Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary

Presentation time: May 31, 2025 (9:00-12:00, Central Standard Time)

Corresponding Author: Meili Sun (Jinan Central Hospital)

Online Publication

Abstract title: Efficacy and safety results of a multi-center Phase I/II study of utidelone capsule, a novel oral microtubule inhibitor.

Abstract ID：e13110

Session: Breast Cancer-Metastatic

First author: Binghe Xu（Cancer Hospital-Chinese Academy of Medical Sciences）